GenSight participated to ESGCT Annual meeting. 

Céline Bouquet, Preclinical Manager at GenSight, gave an oral presentation on “Humoral immune response against AAV2/2-ND4 vector (GS010) after intravitreal administration in non-human primates and patients with Leber Hereditary Optic Neuropathy (LHON)” on Friday 18 September, 2015, session S3c Ocular diseases, 4.00-6.00 pm

The ESGCT Annual Meeting provides an opportunity for scientists, clinicians and industry professionals to share new data, learn from peers, and discover global advances within the Gene and Cell Therapy field. With nearly 1,000 participants from 40 countries, the ESGCT Annual Meeting is this year organised in collaboration with the Finnish Society of Gene Therapy.